Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 8;11:2317. doi: 10.1038/s41467-020-16165-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Antibody neutralization of pseudovirus containing the 92UG037.8 Env determined for non-neutralizing antibodies, including b6 (CD4 binding site; blue), 3791 (V3; cyan), and 17b (CD4-induced; purple), and trimer-specific bnAbs, including PG9 (orange), PG16 (red), and PGT145 (magenta). The CD4 binding site bnAb VRC01, used as a control antibody, is shown in green. b Antibody neutralization of pseudovirus containing the L702S-A756N-D759R mutant. Right panel shows the relative decrease of sensitivity to the trimer-specific bnAbs of double and triple mutants bearing the D759R. c Antibody neutralization of pseudovirus (upper panel) containing a larger number of mutations in the CT (lower panel). d Same as (c) but for the mutant with mutations on the opposite side of the CT–TMD interface. e Same as (c) but for the mutant containing TMD mutations that break the hydrophobic and hydrophilic TMD–CT interactions. Source data are provided as a Source Data file.